Lilly SURMOUNT-5 Substudy Shows Tirzepatide Shifts Epigenetic Clocks Toward Younger Readings at 72 Weeks

At the ARDD conference in October 2026, Lilly presented exploratory data from a SURMOUNT-5 substudy of 71 paired samples, showing that 72 weeks of tirzepatide treatment moved all 15 epigenetic clock readings toward a younger direction, with two reaching significance and median improvements of 1.1 years and 0.7 years. The presentation signals that GLP-1 competition is extending beyond glucose and weight effects, while in China the market is shifting toward competition on distribution capability, pricing strategy and indication coverage.